Overview

A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VX-708 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated